Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MNKD $0.55 0.0700 +14.58%
CASC $5.50 0.5300 +10.66%
BLCM $18.72 1.7400 +10.25%
SYRS $15.47 1.3900 +9.87%
CTIC $0.49 0.0430 +9.73%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TRIL $6.70 -0.5000 -6.94%
MRTX $5.05 -0.2000 -3.81%
BPMC $27.01 -0.9900 -3.54%
RXDX $5.95 -0.2000 -3.25%
LBIO $6.00 -0.2000 -3.23%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

In a First, U.S. Trial to Test Cuban Lung-Cancer Vaccine

(Washington Post/To Your Health) Oct 27, 2016 - The Food and Drug Administration has approved the first clinical trial to test a Cuban drug in the United States — a lung-cancer vaccine developed in Havana.
read article (free registration required) 

Encouraging Initial Results for iph4102 Presented at the Third World Congress of Cutaneous Lymphomas

(Innate Pharma) Oct 26, 2016 - Innate Pharma SA, today announces encouraging preliminary safety and clinical activity results from the dose-escalation part of the Phase I study testing IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas (“CTCL”), an orphan disease. IPH4102 is Innate Pharma’s wholly-owned, first-in-class anti-KIR3DL2 humanized therapeutic antibody, designed to trigger immune cell-mediated killing of CTCL cancer cells.
read corporate press release 

U.S. FDA Adds Abuse Warning to Prescription Testosterone

(Reuters) Oct 25, 2016 - Drugs used to treat low testosterone will carry a new warning about the potential risk of abuse, the U.S. Food and Drug Administration said on Tuesday.
read article 

An Alternative To The EpiPen Is Coming Back To Drugstores

(NPR/Shots blog) Oct 26, 2016 - The EpiPen, the anti-allergy device that's been under investigation because of huge price increases, is soon going to have some competition.
read article 

The Challenge Of Providing Early Access To Potential Life-Saving Drugs

(Forbes) Oct 26, 2016 - Not all decisions of the FDA are black and white. On one hand, the agency is charged with the responsibility of protecting the public from dangerous and/or ineffective drugs.
read article 

The Future Of Health Care Is In Data Analytics

(Forbes) Oct 26, 2016 - Every minute of the day, eCare21, a remote patient-monitoring system, collects thousands of pieces of health data about more than 1,000 senior citizens. The telehealth system uses smartphones, Fitbits, Bluetooth and sensors to collect information about things like blood pressure, physical activity, glucose levels, medication intake and weight.
read article 

Trump, Clinton Spar Over Obamacare; Campaign Ends Big-Ticket Fundraisers

(Washington Post) Oct 25, 2016 - Republican presidential candidate Donald Trump on Tuesday argued that spikes in health insurance premiums for Affordable Care Act plans provided an urgent rationale for his election on day that also brought fresh signs of a flagging campaign.
read article (free registration required) 

Why Is It So Hard for Patients With Metastatic Cancer to Participate In Clinical Trials?

(Philadelphia Inquirer/Health blog) Oct 26, 2016 - “Why don’t more cancer patients participate in clinical trials?” asked an oncologist on the panel.
read article 

U.S. Health Care System is Progressing in the Adoption of Alternative Payment Models that Promote Quality and Value

(LAN) Oct 25, 2016 - A report released today by the Health Care Payment Learning & Action Network (LAN) finds that progress is being made across the country to improve quality, reduce costs, and provide better health outcomes for patients through the adoption of alternative payment models (APMs).
read press release 

New Leadership Elected to American Society of Hematology

(ASH) Oct 26, 2016 - The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the election of four new members to its Executive Committee for terms beginning after the 2016 ASH Annual Meeting December 3-6 in San Diego.
read press release 

How Can Practices Seek Success With Oncology Payment Reform?

(AJMC) Oct 25, 2016 - At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance (COA), held October 24-25, 2016, in Tyson’s Corner, Virginia, Bruce Gould, MD, medical director, Northwest Georgia Oncology Center, presented an overview of how cancer care has improved over the years, what the challenges are, and how practices can adapt to payment reform.
read article 

New Website to Help Cancer Survivors Manage Health

(ACS) Oct 26, 2016 - The American Cancer Society and the National Cancer Institute have launched an easy-to-use website to help cancer survivors during and after cancer treatment.
read press release 

Access 2015 PQRS and QRUR Reports to Determine 2017 Payment Adjustments for Your Practice

(ASCO in Action) Oct 25, 2016 - In late September, the Centers for Medicare and Medicaid Services (CMS) released the 2015 Physician Quality Reporting System (PQRS) Feedback Reports and 2015 Annual Quality and Resource Use Reports (QRURs). These reports are used to determine whether a practice will receive bonuses or be subject to PQRS and Value Modifier payment penalties in 2017.
read article 

Novartis Looks at Up to $5 Billion Deals in Cancer, Generics

(Bloomberg/Markets blog) Oct 25, 2016 - Novartis AG, Europe’s second-biggest drugmaker by sales, said it’s looking for acquisitions that cost between $2 billion and $5 billion to bolster its position in areas including cancer and the development of copycat medicines.
read article 

Strategies for OCM Implementation at the COA Payer Summit

(AJMC) Oct 25, 2016 - What are some of the challenges that clinical practices will face as they implement the Medicare Oncology Care Model (OCM)? What are some of the strategies that have worked for practices using similar payment models?
read article 

Terminally Ill Cancer Patients Fare Poorly After Surgery

(UC Davis Health System) Oct 25, 2016 - Patients with disseminated advanced cancer who undergo surgery are far more likely to endure long hospital stays and readmissions, referrals to extended care facilities and death, UC Davis researchers have found.
read press release 

IU Research Reveals Link Between Molecular Mechanisms in Prostate Cancer and Ewing's Sarcoma

(Indiana University) Oct 25, 2016 - Medical researchers at Indiana University Bloomington have found evidence for a link between prostate cancer, which affects millions of men age 50 and older, and Ewing's sarcoma, a rare form of cancer that affects children and young adults.
read press release 

Fat in Feces Points to Early Presence of Colorectal Cancer

(WSU News) Oct 25, 2016 - Scientists at Washington State University and Johns Hopkins Medical School have discovered a fast, noninvasive method that could lead to the early diagnosis of colorectal cancer.
read article 

Nonsurgical Treatment of Rectal Cancer Questioned

(MedPage Today) Oct 25, 2016 - Nonsurgical management of nonmetastatic rectal cancer led to worse survival compared with upfront surgery, a retrospective review of a national database showed, contradicting data from several recent studies.
read article (free registration required) 

Myriad's BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit From Second-Line Maintenance Treatment with Olaparib

(Myriad Genetics) Oct 26, 2016 - Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDx® test accurately identified patients who may benefit from treatment with olaparib. The BRACAnalysis CDx test was included in the SOLO2 study (NCT01874353) as a diagnostic with olaparib, an oral PARP inhibitor being developed by AstraZeneca.
read corporate press release 

OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial in Metastatic Bladder Cancer

(OncoGenex) Oct 25, 2016 - OncoGenex Pharmaceuticals, Inc. announced today positive survival results from the final analysis of the Phase 2 Borealis-2™ trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy.
read corporate press release 

LYNPARZATM (olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit

(StreetInsider) Oct 26, 2016 - AstraZeneca today announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LYNPARZATM (olaparib) tablets (300mg twice daily) as a monotherapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.
read article 

Rates Up 22 Percent For Obamacare Plans, But Subsidies Rise, Too

(NPR/Shots blog) Oct 24, 2016 - The cost of health insurance under the Affordable Care Act is expected to rise an average of 22 percent in 2017, according to information released by the Obama administration Monday afternoon.
read article 

Novartis CEO Sees Tougher U.S. Drug Pricing over next Three-Five Years

(Reuters) Oct 25, 2016 - Novartis expects a more difficult pricing environment for drugs in the United States in the years ahead, its chief executive told a results conference call on Tuesday.
read article 

AARP Sues U.S. Agency Over Employee Wellness Programs

(Reuters) Oct 24, 2016 - A lobbying group representing older Americans sued the Obama administration on Mondayclaiming regulations for programs designed to rein in employee health care costs will subject workers to invasions of their medical privacy.
read article